-
公开(公告)号：US11986294B2
公开(公告)日：2024-05-21
申请号：US18325564
申请日：2023-05-30
Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Inventor： Boris P. Kovatchev , Marc D. Breton , Stephen D. Patek
CPC classification number: A61B5/14532 , A61B5/0002 , A61B5/0004 , A61B5/4839 , A61B5/7275 , A61B5/746 , A61M5/1723 , G16H20/17 , G16H40/63 , G16H50/50 , G16H40/67
Abstract: An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
-
公开(公告)号：US20240148665A1
公开(公告)日：2024-05-09
申请号：US18495741
申请日：2023-10-26
Applicant: University of Virginia Patent Foundation
Inventor： Anuradha Illendula , Samir Zuberi , Alex Powell
CPC classification number: A61K9/5123 , A61K31/7105 , A61K47/10 , A61K47/24 , A61K47/26 , A61K47/28
Abstract: Provided are compositions that include compositions of galactosyl-conjugated lipid nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl-conjugated LNPs have a lipid component having D-Lin-MC3-DMA, ALC-0315 and SM-102, cholesterol. DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GalNAc-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GalNAc-conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated with undesirable PCSK9 gene expression, optionally a cardiovascular disease, disorder, or condition, including but not limited to atherosclerosis and/or thrombosis, and sepsis, septic shock, cytokine storm, or sequelae thereof.
-
23.发明公开公开(公告)号：US20240139354A1
公开(公告)日：2024-05-02
申请号：US18407111
申请日：2024-01-08
Inventor： James Radford Stone , Kiel Douglas Neumann , Matthew Robert Dreher
CPC classification number: A61K51/1244 , A61B6/037 , A61K51/02 , A61N5/1001 , A61N2005/1021 , A61N2005/1052
Abstract: Some embodiments relate to imageable radioisotopic microspheres. In some embodiments, the imageable microspheres are radiolabeled with imageable radioisotopes. In some embodiments, the imageable radioisotope is directly coupled to a surface of a substrate of the microsphere. In some embodiments, the imageable microspheres can be used as surrogate particles to predict the distribution of therapeutic microspheres comprising radiotherapeutic isotopes.
-
24.发明公开公开(公告)号：US20240138770A1
公开(公告)日：2024-05-02
申请号：US18500403
申请日：2023-11-02
Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Inventor： Boris P. KOVATCHEV , Chiara FABRIS , Marcela MOSCOSO-VASQUEZ
CPC classification number: A61B5/7214 , A61B5/1451 , A61B5/14532 , A61B5/4839 , A61B5/6849 , A61B5/6885 , A61B5/746 , A61B2560/0475
Abstract: Embodiments can relate to systems and methods for automatically detecting sensor compression in continuous glucose monitoring in real time. A system may include at least one sensor and at least one processor in communication with the at least one sensor. The at least one processor is programmed or configured to cause the processor to retrieve first measurement data including at least one time series of blood glucose (BG) measurements, the at least one time series being measured by the at least one sensor while not subject to compression; receive, from the at least one sensor, second measurement data including at least one BG measurement; determine a clearance value between BG measurements based on the first measurement data and the second measurement data; and generate a signal output indicating that the at least one sensor is subject to compression based on the clearance value between BG measurements exceeding a predefined threshold.
-
公开(公告)号：US11957682B2
公开(公告)日：2024-04-16
申请号：US17809145
申请日：2022-06-27
Applicant: University of Virginia Patent Foundation
Inventor： Hui Li , Zhongqiu Xie
IPC: A61K31/506 , A61K31/40 , A61K31/454 , A61K45/06 , A61P35/04
CPC classification number: A61K31/506 , A61K31/40 , A61K31/454 , A61P35/04 , A61K45/06
Abstract: In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
-
Patent Agency Ranking
26.发明授权公开(公告)号：US11954578B2
公开(公告)日：2024-04-09
申请号：US17605078
申请日：2020-04-24
Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Inventor： Craig H Meyer , Xue Feng
CPC classification number: G06N3/045 , A61B5/055 , G01R33/5608 , G06N3/047 , G06N3/088 , G06T5/002 , G06T2200/04 , G06T2207/10092 , G06T2207/30016
Abstract: Systems and methods for denoising a magnetic resonance (MR) image utilize an unsupervised deep convolutional neural network (U-DCNN). Magnetic resonance (MR) image data of an area of interest of a subject can be acquired, which can include noisy input images that comprise noise data and noise free image data. For each of the noisy input images, iterations can be run of a converging sequence in an unsupervised deep convolutional neural network. In each iteration, parameter settings are updated; the parameter settings are used in calculating a series of image feature sets with the U-DCNN. The image feature sets predict an output image. The converging sequence of the U-DCNN is terminated before the feature sets predict a respective output image that replicates all of the noise data from the noisy input image. Based on a selected feature set, a denoised MR image of the area of interest of the subject can be output.
-
公开(公告)号：US11945825B2
公开(公告)日：2024-04-02
申请号：US17365528
申请日：2021-07-01
Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Inventor： Kyle Hoehn , Brandon Kenwood
IPC: C07D498/04 , A61K9/00 , A61K31/4985 , G01N33/50
CPC classification number: C07D498/04 , A61K9/0053 , A61K31/4985 , G01N33/5014 , G01N33/5079 , G01N2500/10
Abstract: The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.
-
公开(公告)号：US20240085429A1
公开(公告)日：2024-03-14
申请号：US18273728
申请日：2022-01-24
Inventor： Anne Kathleen Kenworthy , Nico Fricke , Ajit Tiwari , Charles R. Sanders , Krishnan Raghunathan , Hui Huang , Ricardo F. Capone , Joshua A. Bauer , Katherine M. Stefanski
CPC classification number: G01N33/582 , G01N21/6428 , G01N33/92 , G01N2021/6441 , G01N2500/20
Abstract: Disclosed are methods, including automated methods, for identifying a compound that impacts a characteristic of a lipid raft phase domain, a characteristic of a non-raft phase domain, and/or a characteristic of one or more membrane proteins. In some embodiments, the method comprises contacting a population of vesicles with a candidate compound, wherein a population of vesicles, wherein one or more vesicles in the population of optionally comprises one or more membrane proteins, with a candidate compound, wherein in a portion of the population of vesicles there is only a single detectable membrane phase and in a portion of the population of vesicles a membrane lipid raft phase domain and a membrane non-raft phase domain are phase separated; detecting a signal from the population of vesicles; and identifying the candidate compound as having an impact on a characteristic of a lipid raft phase domain, a characteristic of a non-raft phase domain, and/or a characteristic of one or more membrane proteins based on the signal. Systems and non-transitory computer readable medium comprising computer executable instructions embodied in a computer readable medium that when executed by a processor of a computer control the computer to perform steps of the method are also disclosed.
-
公开(公告)号：US11904068B2
公开(公告)日：2024-02-20
申请号：US17651509
申请日：2022-02-17
Applicant: University of Virginia Patent Foundation
Inventor： John C. Herr , Alexander L. Klibanov , Kevin Simon Eisenfrats
IPC: A61B17/34 , A61F6/22 , A61L24/00 , A61L24/06 , A61L27/52 , A61L27/54 , A61K49/22 , A61B8/08 , A61B17/12 , A61B17/42
CPC classification number: A61L24/06 , A61B8/085 , A61B8/0833 , A61B8/0841 , A61B17/12 , A61B17/12022 , A61B17/12186 , A61B17/3403 , A61F6/22 , A61K49/223 , A61K49/226 , A61L24/001 , A61L24/0015 , A61L24/0031 , A61L24/0036 , A61L27/52 , A61L27/54 , A61B8/0891 , A61B8/481 , A61B8/488 , A61B17/42 , A61B2017/3413 , A61L2300/626 , A61L2400/06 , A61L2430/36
Abstract: Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.
-
30.发明公开公开(公告)号：US20240050602A1
公开(公告)日：2024-02-15
申请号：US18264347
申请日：2022-02-07
Applicant: University of Virginia Patent Foundation
Inventor： James Radford Stone , Kiel Douglas Neumann
CPC classification number: A61K51/1251 , A61K51/025 , A61P35/00 , A61N5/1007 , G21G4/08 , A61N2005/1021
Abstract: Some embodiments relate to therapeutic radioisotopic particles. In some embodiments, the therapeutic particles are radiolabeled with therapeutic radioisotopes. In some embodiments, the therapeutic particles can be in the treatment of cancer of the liver. In some embodiments, the therapeutic particles are radiolabeled with therapeutic radioisotopes. In some embodiments, the therapeutic radioisotope is directly coupled to a surface of a substrate of the particle.
-
-
-
-
-
-
-
-
-
Search Results
1063
records
(took 0.022 seconds)
